Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Changes in medication adherence and unused drugs after switching from daily dipeptidyl peptidase-4 inhibitors to once-weekly trelagliptin in patients with type 2 diabetes.

Ito H, Ando S, Tsugami E, Araki R, Kusano E, Matsumoto S, Uemura K, Nishio S, Antoku S, Yamasaki T, Mori T, Togane M.

Diabetes Res Clin Pract. 2019 May 28;153:41-48. doi: 10.1016/j.diabres.2019.05.025. [Epub ahead of print]

PMID:
31150724
2.

Randomized Multicenter Evaluation of Quality of Life and Treatment Satisfaction in Type 2 Diabetes Patients Receiving Once-Weekly Trelagliptin Versus a Daily Dipeptidyl Peptidase-4 Inhibitor.

Ishii H, Suzaki Y, Miyata Y, Matsui S.

Diabetes Ther. 2019 Aug;10(4):1369-1380. doi: 10.1007/s13300-019-0643-1. Epub 2019 Jun 18.

PMID:
31214997
3.

Satisfaction and efficacy of switching from daily dipeptidyl peptidase-4 inhibitors to weekly trelagliptin in patients with type 2 diabetes-Randomized controlled study.

Oita M, Miyoshi H, Ono K, Nakamura A, Cho KY, Nomoto H, Yamamoto K, Omori K, Manda N, Kurihara Y, Aoki S, Atsumi T.

Endocr J. 2018 Feb 26;65(2):141-150. doi: 10.1507/endocrj.EJ17-0303. Epub 2017 Oct 31.

4.
5.

Safety evaluation of trelagliptin in the treatment of Japanese type 2 diabetes mellitus patients.

Kaku K.

Expert Opin Drug Saf. 2017 Nov;16(11):1313-1322. doi: 10.1080/14740338.2017.1369526. Epub 2017 Aug 29. Review.

PMID:
28829213
6.

First novel once-weekly DPP-4 inhibitor, trelagliptin, for the treatment of type 2 diabetes mellitus.

Kaku K.

Expert Opin Pharmacother. 2015;16(16):2539-47. doi: 10.1517/14656566.2015.1099630. Epub 2015 Nov 2. Review.

PMID:
26523434
7.

Efficacy and Patient Satisfaction of the Weekly DPP-4 Inhibitors Trelagliptin and Omarigliptin in 80 Japanese Patients with Type 2 Diabetes.

Tosaki T, Kamiya H, Yamamoto Y, Himeno T, Kato Y, Kondo M, Yamada Y, Inagaki A, Tsubonaka K, Oshiro C, Katayama T, Hayasaki T, Nakaya Y, Fujiyoshi H, Nakamura J.

Intern Med. 2017 Oct 1;56(19):2563-2569. doi: 10.2169/internalmedicine.8184-16. Epub 2017 Sep 6.

8.

[Once-weekly DPP-4 inhibitor].

Harada N, Inagaki N.

Nihon Rinsho. 2015 Dec;73(12):2096-102. Japanese.

PMID:
26666159
9.

Effect of Trelagliptin on Quality of Life in Patients with Type 2 Diabetes Mellitus: Study Protocol.

Ishii H, Suzaki Y, Miyata Y.

Diabetes Ther. 2017 Dec;8(6):1415-1425. doi: 10.1007/s13300-017-0318-8. Epub 2017 Oct 26.

10.

Efficacy and Patient Satisfaction of Dipeptidyl Peptidase-4 Inhibitor After Switching From Once-Daily DPP-4 Inhibitor to Once-Weekly Regimen.

Suzuki K, Hasegawa K, Watanabe M.

J Clin Med Res. 2018 Aug;10(8):641-647. doi: 10.14740/jocmr3456w. Epub 2018 Jun 27.

11.

Once-weekly trelagliptin versus daily alogliptin in Japanese patients with type 2 diabetes: a randomised, double-blind, phase 3, non-inferiority study.

Inagaki N, Onouchi H, Maezawa H, Kuroda S, Kaku K.

Lancet Diabetes Endocrinol. 2015 Mar;3(3):191-7. doi: 10.1016/S2213-8587(14)70251-7. Epub 2015 Jan 19.

PMID:
25609193
13.

Once-weekly dipeptidyl peptidase-4 inhibitors for type 2 diabetes: a systematic review and meta-analysis.

Stoimenis D, Karagiannis T, Katsoula A, Athanasiadou E, Kazakos K, Bekiari E, Matthews DR, Tsapas A.

Expert Opin Pharmacother. 2017 Jun;18(9):843-851. doi: 10.1080/14656566.2017.1324848. Epub 2017 May 9. Review.

PMID:
28448177
14.

Trelagliptin (SYR-472, Zafatek), Novel Once-Weekly Treatment for Type 2 Diabetes, Inhibits Dipeptidyl Peptidase-4 (DPP-4) via a Non-Covalent Mechanism.

Grimshaw CE, Jennings A, Kamran R, Ueno H, Nishigaki N, Kosaka T, Tani A, Sano H, Kinugawa Y, Koumura E, Shi L, Takeuchi K.

PLoS One. 2016 Jun 21;11(6):e0157509. doi: 10.1371/journal.pone.0157509. eCollection 2016.

15.

Discovery of a Natural-Product-Derived Preclinical Candidate for Once-Weekly Treatment of Type 2 Diabetes.

Li S, Qin C, Cui S, Xu H, Wu F, Wang J, Su M, Fang X, Li D, Jiao Q, Zhang M, Xia C, Zhu L, Wang R, Li J, Jiang H, Zhao Z, Li J, Li H.

J Med Chem. 2019 Mar 14;62(5):2348-2361. doi: 10.1021/acs.jmedchem.8b01491. Epub 2019 Feb 13. Erratum in: J Med Chem. 2019 May 9;62(9):4779.

PMID:
30694668
16.

Effect of trelagliptin on vascular endothelial functions and serum adiponectin level in patients with type 2 diabetes: a preliminary single-arm prospective pilot study.

Ida S, Murata K, Betou K, Kobayashi C, Ishihara Y, Imataka K, Uchida A, Monguchi K, Kaneko R, Fujiwara R, Takahashi H.

Cardiovasc Diabetol. 2016 Nov 4;15(1):153.

17.
18.

SYR-472, a novel once-weekly dipeptidyl peptidase-4 (DPP-4) inhibitor, in type 2 diabetes mellitus: a phase 2, randomised, double-blind, placebo-controlled trial.

Inagaki N, Onouchi H, Sano H, Funao N, Kuroda S, Kaku K.

Lancet Diabetes Endocrinol. 2014 Feb;2(2):125-32. doi: 10.1016/S2213-8587(13)70149-9. Epub 2013 Nov 1.

PMID:
24622716
19.

Trelagliptin: First Global Approval.

McKeage K.

Drugs. 2015 Jul;75(10):1161-4. doi: 10.1007/s40265-015-0431-9. Review.

PMID:
26115728
20.

Effect of switching to teneligliptin from other dipeptidyl peptidase-4 inhibitors on glucose control and renoprotection in type 2 diabetes patients with diabetic kidney disease.

Kitada M, Ogura Y, Nitta K, Fujii M, Kanasaki K, Konishi K, Iida Y, Nakagawa A, Koya D.

J Diabetes Investig. 2019 May;10(3):706-713. doi: 10.1111/jdi.12917. Epub 2018 Oct 1.

Supplemental Content

Support Center